Forgot Password?
Return to Course Listing

CME: Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies

Activity Description / Statement of Need:

In this online, self-learning activity:

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease (CD), the former of which exclusively affects the colon and rectum. UC occurs more frequently than CD, with an incidence of 1.2 to 20.3 cases per 100,000 persons per year and a prevalence of 7.6 to 246.0 cases per 100,000 per year, as compared to 0.03 to 15.6 and 3.6 to 214.0 per 100,000 for CD. Risk factors include characteristics common in westernized environments and lifestyles, including smoking, diets high in fat and sugar, medication use, stress, and high socioeconomic status.

Target Audience:

HCPs specializing in: gastroenterology, internal medicine; nurse practitioners, physician assistants, and pharmacists who specialize in gastroenterology; and those who otherwise commonly care for or clinically encounter patients with UC.


This program is supported by an educational grant from Amgen.


Release Date: July 22, 2020 -- Expiration Date: July 22, 2022

Faculty: Mark Mattar, MD

Agenda

Faculty introduction, disclosures

Epidemiology and clinical features of UC

  • Statistics by severity
  • Causes and risk factors
  • Clinical features: endoscopic, radiologic, and histopathologic
  • Burden of disease, health-related quality of life

Treatment of UC

  • UC professional guidelines
  • Medications for induction and maintenance therapy for UC: salicylates, including novel formulations; glucocorticoids; immunomodulators; biologicals
  • Novel and emerging therapies and approaches to the treatment of UC
  • Adherence to therapy and modifiable factors that may exacerbate the disease course
  • The role of teaching and communication strategies in strengthening the patient-provider compact
  • Patient case(s)

Best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the burden of disease UC represents to patients.
  • Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
  • Identify new and emerging therapies for the treatment of UC.
  • Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physicians: For applicable courses, to attain maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in the "Accreditation" section on this page, then it does NOT provide MOC credit.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.75 hours (0.075 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-20-031-H01-P.  ACPE Accreditation effective 07/22/2020, expires 07/22/2022. This is a Knowledge (K)-type activity.

 

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
 

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Mark C. Mattar, MD, FACG, AGAF, Associate Professor of Medicine, Director, Fellowship Training Program, Director, IBD Center, MedStar Georgetown University Hospital, has received financial compensation as a consultant and speakers bureau from AbbVie, Janssen, Takeda, and Pfizer. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.

Commercial Support Disclosure: This program is supported by an educational grant from Amgen.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting

Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?

Pediatric Crohn's disease: Therapeutic updates and optimizing treatment

Short bowel syndrome: therapeutic updates and optimizing treatment